Post date
10/09/2020
Even when cured, people with Covid-19 have significant sequelae: neurological or cardiovascular disorders, fatigue, loss of respiratory efficiency…
Ath, September 10, 2020 - Botalys has developed a
Post date
02/09/2020
Promethera® Biosciences SA, a global innovator in cell-based medicines and liver diseases, based in Wallonia, Belgium, today announced that John Tchelingerian, PhD, has resigned from his position as
Post date
29/07/2020
Mont-Saint Guibert, Belgium, 29 July, 2020: Novadip Biosciences ("Novadip" or "the Company"), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform
Post date
23/07/2020
CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
Post date
02/07/2020
Post date
01/07/2020
1st July 2020 – Award-winning start-up e-peas continues to underline its reputation as the go-to supplier of advanced energy harvesting solutions, having just completed its latest funding round.
Wi
Post date
04/06/2020
Unique 3M3 tissue regeneration technology platform generates multiple product candidates: autologous, off-the-shelf and miRNA/exosome
Mont-Saint Guibert, Belgium, 4 June, 2020: Novadip Biosciences (
Post date
28/05/2020
Animal health company focused on combatting viral infections in livestock
LEUVEN, Belgium, May 28th, 2020 — ViroVet NV, a leading Belgian biopharmaceutical company active in the development of
Post date
14/05/2020
- Axinesis, the Walloon company specialized in medical devices for neurological rehabilitation, announces the CE mark for its new product, the REAtouch®.
- It is a medical device for patients
Post date
28/04/2020
– Initial data from the dose escalation portion of the Phase 1/2a trial in 21 cancer patients with advanced solid tumors shows EOS-850 was well tolerated with no dose-limiting toxicities observed –
–
Post date
01/04/2020
Walloon biotech iTeos Therapeutics completes a new round of $125 million with historical investors and 5 new leading U.S. funds active in initial public offering (IPO). This is one of the largest
Post date
30/03/2020
As of February 21st, Prof. Etienne Sokal, M.D., Ph.D., has stepped back from his operational role as Group CMO and will transition to the position of Chairman of Promethera®’s Scientific & Medical